Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TTHX1114 in corneal endothelial dystrophy
NCT04812067Phase 2Completed
- Sponsor
- Trefoil Therapeutics
- Start
- Nov 2021
- Primary completion
- Aug 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of TTHX1114 in Fuchs endothelial dystrophy (FED), sponsored by Trefoil Therapeutics. Started Nov 2021; status: completed.
02
Drugs
TTHX1114
03
Conditions
Fuchs endothelial dystrophy (FED)
Beyond the preview
Go deeper on NCT04812067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04812067.